Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs
Publication date
2023-03-31
Authors
Damen, Pim J J
Verhoeff, Joost J C
Editors
Advisors
Supervisors
Document Type
Editorial
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Keywords
Checkpoint inhibitors, Response Evaluation Criteria in Solid Tumors (RECIST), abscopal response, oligoprogression, radiotherapy, Editorial, Comment
Citation
Damen, P J J & Verhoeff, J J C 2023, 'Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs', Translational Cancer Research, vol. 12, no. 3, pp. 688-691. https://doi.org/10.21037/tcr-22-2841